These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27541605)

  • 1. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.
    Yamagiwa Y; Asano M; Kawasaki Y; Korenaga M; Murata K; Kanto T; Mizokami M; Masaki N
    Cytokine; 2016 Dec; 88():29-36. PubMed ID: 27541605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
    Zhang R; Shao C; Huo N; Li M; Xu X
    Gut Liver; 2016 May; 10(3):446-55. PubMed ID: 26470765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
    Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
    Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.
    Abd El-Maksoud E; Salem AM; Maher AM; Hegazy MGA
    Trop Biomed; 2020 Dec; 37(4):1083-1092. PubMed ID: 33612760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients.
    Wang J; Jiang D; Rao H; Yang R; Wang Y; Wei L
    Scand J Gastroenterol; 2014 Nov; 49(11):1349-58. PubMed ID: 25263691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
    Nakagawa A; Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Arai T; Hashimoto S; Matsushita Y; Fukuda T; Nakatsuka K; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1329-34. PubMed ID: 25357216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.
    Derbala M; Rizk NM; Al-Kaabi S; John A; Sharma M; El-dweik N; Yakoob R; Pasic F; Almohanadi M; Alejji K; Abdelmola A; Butt M
    Virology; 2013 Sep; 444(1-2):292-300. PubMed ID: 23866096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
    Darling JM; Aerssens J; Fanning G; McHutchison JG; Goldstein DB; Thompson AJ; Shianna KV; Afdhal NH; Hudson ML; Howell CD; Talloen W; Bollekens J; De Wit M; Scholliers A; Fried MW
    Hepatology; 2011 Jan; 53(1):14-22. PubMed ID: 21254158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.
    Matsuura K; Watanabe T; Iijima S; Murakami S; Fujiwara K; Orito E; Iio E; Endo M; Kusakabe A; Shinkai N; Miyaki T; Nojiri S; Joh T; Tanaka Y
    Hepatol Res; 2014 Nov; 44(12):1208-1216. PubMed ID: 24372894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
    Arnaud C; Pradat P; Spaziante M; Berthillon P; Maynard M; Taliani G; Chemin I; Trépo C; Petit MA
    Antivir Ther; 2013; 18(8):1027-32. PubMed ID: 23948510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.
    Petta S; Ferraro D; Cammà C; Cabibi D; Di Cristina A; Di Marco V; Di Stefano R; Grimaudo S; Mazzola A; Levrero M; Scazzone C; Craxì A
    Antivir Ther; 2012; 17(5):823-31. PubMed ID: 22505587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
    Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.